E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Glycogen Storage Disease type II (Pompe's disease) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036143 |
E.1.2 | Term | Pompe's disease |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The overall objective is to evaluate the safety, efficacy, and pharmacokinetics (PK) of Myozyme treatment in patients with late-onset Pompe disease as compared to placebo.
The primary objectives of the study are: 1) to evaluate the safety profile of Myozyme; 2) to determine the effect of Myozyme treatment on functional endurance as measured by the Six Minute Walk Test (6MWT) 3) to determine the effect of Myozyme treatment on respiratory muscle weakness as measured by Forced Vital Capacity (FVC) in the upright position ; and 4) to determine in a subset of patients the PK profile of Myozyme in patients with late-onset Pompe disease. The study wil be considered to have met its primary efficacy objective if a statistically significant treatment effect of Myozyme over placebo is demonstrated in the 6 MWT distance walked. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are: 1) to determine the effect of Myozyme treatment on proximal muscle weakness in the lower limbs as measured by Quantitative Muscle Testing (QMT) in bilateral knee flexors (hamstrings) and knee extensors (quadriceps); 2) to determine the effect of Myozyme treatment on health-related quality of life as measured by the Physical Component Summary (PCS) score of the Medical Outcomes Study (MOS) SF-36. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. The patient must provide signed, informed consent prior to performing any study-related procedures. Consent of a legally authorized guardian(s) is (are) required for patients under 18 years of age. If the patient is under 18 years of age and can understand the written informed consent, signature will be required from both the patient and the authorized guardian(s); 2. The patient must have a diagnosis of Pompe disease based on deficient endogenous GAA activity in cultured skin fibroblasts of ≤ 40% of the normal mean of the testing laboratory and 2 confirmed GAA gene mutations; 3. The patient must be ≥ 8 years of age at the time of enrollment; 4. The patient must have muscle weakness in the lower limbs based on unilateral QMT of the knee extensors defined as < 80% of the predicted value based on age, gender and body size (The National Isometric Muscle Strength [NIMS] Database Consortium, 1996, Arch Phys Med Rehabil); 5. The patient must be able to tolerate pulmonary function testing (PFT) and muscle testing in the supine position. (See exclusion criteria [1] and [2].); 6. The patient must be able to provide reproducible muscle and pulmonary function test results (bilateral QMT measurements [% predicted] in knee extensors within 10% of the highest test value obtained from the same side of the body on 2 consecutive days and FVC measurements [in liters] within 10% of the highest test value obtained in the upright position on 2 consecutive days); 7. The patient must have an FVC of ≥ 30% and < 80% predicted in the upright position (American Thoracic Society [ATS], 1991, Am Rev Respir Disease); 8. The patient must have an FEV1/FVC value of ≥ 70% predicted in the upright position (ATS, 1991, Am Rev Respir Disease); 9. The patient must have a postural drop in FVC (liters) of at least 10% from the upright to the supine position [(FVC supine (L) – FVC upright (L))/FVC upright (L)] * 100%; 10. The patient must have testable muscle in bilateral knee flexors and knee extensors, and testable muscle in bilateral elbow flexors and elbow extensors. (Using QMT, a muscle will be defined as “not testable” if the patient: 1) has a contracture > 90 degrees that would keep them from being able to assume the standard testing position, 2) is unable to follow directions, 3) has significant pain with resistance to the motion, or 4) is so weak that force cannot be generated against the testing strap); 11. The patient must be able to ambulate 40 meters (approximately 130 feet) in 6 minutes on each of 2 consecutive tests performed on the same day (use of assistive devices such as a walker, cane, or crutches, is permitted); 12. The patient (and patient’s legal guardian if patient <18 years of age) must have the ability to comply with the clinical protocol; 13. A female patient of childbearing potential must have a negative pregnancy test (urine beta-human chorionic gonadotropin [β-hCG]) at Baseline. Note: All female patients of childbearing potential and sexually mature males must use a medically accepted method of contraception throughout the study.
|
|
E.4 | Principal exclusion criteria |
1. The patient requires the use of invasive ventilatory support. (Invasive ventilation is defined as any form of ventilatory support applied with the use of an endotracheal tube.); 2. The patient requires the use of noninvasive ventilatory support while awake and in an upright position. (Noninvasive ventilation is defined as any form of ventilatory support applied without the use of an endotracheal tube. For example, patients receiving positive-pressure ventilation support through a facemask or nose piece are considered as ventilated through noninvasive methods.); 3. The patient has received enzyme replacement therapy with GAA from any source; 4. The patient has used an investigational product within 30 days prior to study enrollment, or is currently enrolled in another study which involves clinical evaluations, unless prior approval is given by Genzyme; 5. The patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities; 6. The patient has a major congenital anomaly. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
See objectives section (E2).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |